2026-05-18
Beyond organ transplantation, this non-toxic low-temperature preservation framework can be extended to long-term storage of stem cells, reproductive cells, and germplasm resources of endangered species, providing a universal technological foundation for biobanks, regenerative medicine, and other fields.
2026-05-11
As this technology continues to mature, we are moving one step closer to an era of safe, long-term, high-fidelity human-computer interaction.
2026-05-11
Smart Hydrogel Ushers Bone Regeneration into the Era of "Living Materials"
In the future, implanted materials will no longer be "dead scaffolds" but living materials that can converse with cells and adapt along with them.
2026-04-29
The clinical value of this approach lies in its extremely simple operation. It requires no specialized cryopreservation solutions or complex equipment, using only GMP‑grade compliant cytokines that can be removed by routine washing after pretreatment, posing no additional safety risks to patients and enabling rapid integration into existing cell production and cryopreservation workflows. As the large‑scale manufacturing of NK cells derived from umbilical cord blood and iPSCs becomes increasingly mature, combining this cryopreservation technology holds the potential to significantly reduce cell therapy costs and improve accessibility, opening new avenues for immunotherapy in hematological malignancies and solid tumors.
2026-04-20
Breaking the Bottleneck: New Technology Enables Deep Cryopreservation of Large-Scale Organs
Previously, only limited breakthroughs had been achieved internationally on 1 mL rat kidney models. The 10 mL rabbit kidney allogeneic transplantation achieved by the Technical Institute of Physics and Chemistry marks a milestone step toward clinical application of deep cryopreservation technology. In the future, this technology is expected to be extended to long-term preservation of human-scale organs, bringing revolutionary changes to organ transplantation.
2026-04-20
This breakthrough holds tremendous potential not only for brain-computer interfaces and neural prosthetics (such as auditory, visual, and motor implants) but also lays a solid hardware foundation for building the next generation of efficient, brain-like computing systems.
2026-04-13
The "reversing aging" study that graced the cover of Nature six years ago has finally left the lab and entered human trials. A "partial reprogramming" gene therapy, co-developed by Yuancheng Lu, a former Chinese doctoral student in David Sinclair's lab at Harvard Medical School, has recently received FDA approval to launch the world's first human clinical trial targeting cellular aging reversal. This marks the first time the once sci-fi concept of "rejuvenation" will be scientifically tested in humans.
2026-04-13
As depicted in the review's future blueprint—from smart bioink preparation to hybrid printing processes and stimulated maturation and development—micro/nano-scale 3D bioprinting is steadily bringing the dream of "custom-made organs" closer to reality.
2026-04-02
"This is not just about building robots, but also about treating diseases," Xu Chun reveals. His team is using such digital models to compare differences between diseased and healthy brain connections, precisely locating neural circuit abnormalities.
2026-03-24
The advent of the CAMP platform means that in the future, we may be able to "retrieve" pre-prepared cell-laden bioinks from cell banks as easily as taking out an ice cube, revive them, and immediately use them for 3D printing to construct tissue engineering scaffolds or even organ chips. This breakthrough technology offers a highly promising "ready-to-use" solution for the urgent repair of large tissue defects and the rapid fabrication of personalized implants in clinical settings, with the potential to completely bridge the critical gap from laboratory to operating room.